tips for taking tirzepatide Best time to take shot: the complete timing guide Tirzepatide: A Breakthrough Approach to
Description
Baseline measurements should include body weight, BMI, HbA1c (if diabetic), renal function, and relevant metabolic parameters
Why Personalization Matters GLP-1 therapy has well-known side effects, the most common being nausea, particularly during the first 4 to 8 weeks of dose titration
Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection, Eli Lilly and Company's new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
A study published in the New England Journal of Medicine this month found Zepbound outperformed Wegovy in a head-to-head clinical trial
Higher doses were associated with greater weight loss within the initial 4 weeks of treatment [see Warnings and Precautions (5.5)]
